XML 132 R38.htm IDEA: XBRL DOCUMENT v3.20.4
Other Balance Sheet Components (Tables)
12 Months Ended
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets, as of December 31, 2020 and 2019 consists of the following (in thousands):
December 31,
20202019
Down payments to manufacturing vendors$216,538 $— 
Prepaid expenses
15,647 8,475 
Tenant incentives receivables
10,242 4,093 
Interest receivable on marketable securities
9,725 6,835 
Prepaid expenses and other current assets
$252,152 $19,403 
Schedule of Accrued Liabilities
Accrued liabilities, as of December 31, 2020 and 2019 consists of the following (in thousands):

December 31,
20202019
Clinical trials$97,249 $6,291 
Compensation-related
95,247 27,428 
Raw materials 78,085 — 
Manufacturing53,412 5,872 
Development operations29,253 2,567 
Property and equipment
17,576 4,029 
Commercial6,922 — 
Other external goods and services91,847 21,465 
Accrued liabilities$469,591 $67,652 
Other Current Liabilities
Other current liabilities, as of December 31, 2020 and 2019 consists of the following (in thousands):

December 31,
20202019
Lease liabilities - financing$24,328 $— 
Lease liabilities - operating5,972 3,583 
Other3,365 1,480 
Other current liabilities$33,665 $5,063 
Schedule of Deferred Revenue
The following table presents changes in the balances of our receivables and contract liabilities related to our strategic collaboration agreements during the year ended December 31, 2020 (in thousands):

December 31, 2019AdditionsDeductionsDecember 31, 2020
Contract Assets:
Accounts receivable$1,972 $120,821 $(117,249)$5,544 
Contract Liabilities:
Deferred revenue$199,528 $121,882 $(81,228)$240,182 

During the year ended December 31, 2020, we recognized the following revenue as a result of the change in the contract liability balances related to our collaboration agreements (in thousands):
Revenue recognized in the period from:Year Ended
December 31, 2020
Amounts included in contract liabilities at the beginning of the period (1)
$72,863 
Performance obligations satisfied (or partially satisfied) in previous reporting periods (2)
8,366 

______________
(1) We first allocate revenue to the individual contract liability balance outstanding at the beginning of the period until the revenue exceeds that balance. If additional consideration is received on those contracts in subsequent periods, we assume all revenue recognized in the reporting period first applies to the beginning contract liability.
(2) Related to changes in estimated costs for our future performance obligations and estimated variable considerations.
The following table summarizes the balances of deferred revenue at period end, which is classified as current or non-current in the consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred (in thousands):

December 31,
20202019
Combined AZ Agreements$57,192 $73,669 
The following table summarizes the revenue recognized for the periods presented (in thousands):

Years Ended December 31,
202020192018
2016 VEGF Exercise$14,253 $583 $— 
The following table summarizes the balances of deferred revenue at period end, which is classified as current or non-current in the consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred (in thousands):

December 31,
20202019
2016 VEGF Exercise$29,335 $41,266 
The following table summarizes the revenue recognized for the periods presented (in thousands):

Years Ended December 31,
202020192018
PCV/SAV Agreement$33,103 $41,382 $41,498 
The following table summarizes the balances of deferred revenue, which is classified as current or non-current in the condensed consolidated balance sheets based on the period the services are expected to be performed or control of the supply is expected to be transferred for the periods presented (in thousands):

December 31
20202019
PCV/SAV Agreement$51,007 $83,799 
The following table summarizes the revenue recognized for the periods presented (in thousands):

Years Ended December 31,
202020192018
Vertex First Extended Research Term$13,452 $— $— 
Vertex Agreement/2019 Amendment2,053 6,197 10,400 
Total$15,505 $6,197 $10,400 
The following table summarizes the balances of deferred revenue, classified as current and non-current in the condensed consolidated balance sheets based on the term of the research period for the periods presented (in thousands):

December 31,
20202019
Vertex Agreement (1)
$2,648 $793 
____________
(1) Balance as of December 31, 2019 represents deferred revenue related to the Vertex 2019 Amendment
The following table summarizes the activities in deferred revenue during the year ended December 31, 2020 (in thousands):

December 31, 2019AdditionsDeductionsDecember 31, 2020
Product sales$— $3,881,303 $(82,134)$3,799,169 
Grant revenue2,777 6,775 (4,291)5,261 
Collaboration revenue199,528 121,882 (81,228)240,182 
Total deferred liabilities$202,305 $4,009,960 $(167,653)$4,044,612